Delgocitinib 2% Suppliers & Bulk Manufacturers

Available Forms: Creams

Available Strengths: 2%

Reference Brands: Anzupgo (USA/EU)

Category: Derma Drugs

Delgocitinib is a topical Janus kinase (JAK) inhibitor used to treat moderate-to-severe chronic hand eczema in adults. It works by blocking the JAK-STAT signaling pathway, which reduces inflammation and skin lesions. Applied as a 2% cream to affected areas, it helps control eczema symptoms when topical corticosteroids are insufficient or unsuitable. It is not a systemic drug or narcotic and is used only on the skin.

Product Description:

Delgocitinib is a topical pan-JAK inhibitor, blocking all four Janus kinases — JAK1, JAK2, JAK3 and TYK2. Those enzymes transmit signals from a wide range of inflammatory cytokine receptors, so inhibiting them interrupts several of the pathways that drive eczema at once. Applied to skin, it acts locally with low systemic exposure, which is the point: oral JAK inhibitors carry class warnings for serious infection, thrombosis and malignancy, and a topical formulation is intended to avoid that.

It is used twice daily for moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or unsuitable — a condition that is disabling, often occupational, and until recently had almost no dedicated treatment beyond steroids and oral alitretinoin. In trials it improved disease severity and itch substantially compared with vehicle cream. Local adverse effects are uncommon; application site reactions are mild.

Sourcing notes. Originator product, on patent, no generic. Approved in the European Union in 2024 and by the FDA in 2025, with a paediatric extension under review. Supply is through authorised distribution. Because the indication is narrow and newly defined, reimbursement status largely determines volume in each market.